KR20010040646A - 위장관의 만성 염증성 질환의 치료방법 - Google Patents
위장관의 만성 염증성 질환의 치료방법 Download PDFInfo
- Publication number
- KR20010040646A KR20010040646A KR1020007008518A KR20007008518A KR20010040646A KR 20010040646 A KR20010040646 A KR 20010040646A KR 1020007008518 A KR1020007008518 A KR 1020007008518A KR 20007008518 A KR20007008518 A KR 20007008518A KR 20010040646 A KR20010040646 A KR 20010040646A
- Authority
- KR
- South Korea
- Prior art keywords
- budesonide
- formulation
- treatment
- oil
- oral administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 44
- 210000001035 gastrointestinal tract Anatomy 0.000 title description 14
- 208000037976 chronic inflammation Diseases 0.000 title description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 title description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 50
- 229960004436 budesonide Drugs 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 238000009472 formulation Methods 0.000 claims abstract description 37
- 208000024891 symptom Diseases 0.000 claims abstract description 21
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 16
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 13
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 9
- 239000008158 vegetable oil Substances 0.000 claims abstract description 9
- 239000000725 suspension Substances 0.000 claims description 27
- 241000282326 Felis catus Species 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 235000019198 oils Nutrition 0.000 claims description 15
- 238000013268 sustained release Methods 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 239000008163 avocado oil Substances 0.000 claims description 7
- 235000021302 avocado oil Nutrition 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 3
- 210000002429 large intestine Anatomy 0.000 claims description 3
- 235000005713 safflower oil Nutrition 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 229960005205 prednisolone Drugs 0.000 description 17
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003246 corticosteroid Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 10
- 229960004618 prednisone Drugs 0.000 description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 9
- 208000011231 Crohn disease Diseases 0.000 description 8
- 229960001334 corticosteroids Drugs 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000012053 oil suspension Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- -1 diabetes Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/002265 WO1999039699A1 (en) | 1998-02-09 | 1998-02-09 | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010040646A true KR20010040646A (ko) | 2001-05-15 |
Family
ID=22266344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007008518A Withdrawn KR20010040646A (ko) | 1998-02-09 | 1998-02-09 | 위장관의 만성 염증성 질환의 치료방법 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1052977A4 (https=) |
| JP (1) | JP2002502812A (https=) |
| KR (1) | KR20010040646A (https=) |
| CN (1) | CN1149078C (https=) |
| AU (1) | AU735084B2 (https=) |
| CA (1) | CA2320087C (https=) |
| IL (1) | IL137598A (https=) |
| SE (1) | SE0002831L (https=) |
| WO (1) | WO1999039699A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100333727C (zh) * | 2004-11-25 | 2007-08-29 | 天津药业研究院有限公司 | 布地奈德靶向微丸及其制备方法 |
| MD2852C2 (ro) * | 2005-03-28 | 2006-04-30 | Георге АНГЕЛИЧ | Utilizarea budesonidei pentru tratamentul ascitei rezistente la pacienţii cu ciroză hepatică |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| AU2008215659B2 (en) | 2007-02-16 | 2012-11-01 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
| US20090149433A1 (en) | 2007-11-13 | 2009-06-11 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US8865692B2 (en) | 2007-11-13 | 2014-10-21 | Meritage Pharma, Inc | Compositions for the treatment of gastrointestinal inflammation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643602A (en) * | 1989-11-22 | 1997-07-01 | Astra Aktiebolag | Oral composition for the treatment of inflammatory bowel disease |
| DK0613371T3 (da) * | 1991-12-18 | 2002-05-13 | Astrazeneca Ab | Ny kombination af formoterol og budesonid |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| GB9409778D0 (en) * | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
| GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| WO1998005310A1 (fr) * | 1996-08-02 | 1998-02-12 | Hisamitsu Pharmaceutical Co., Inc. | Gelules destinees a des preparations orales et preparations de gelules destinees a une administration orale |
| KR100219918B1 (ko) * | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
-
1998
- 1998-02-09 CA CA002320087A patent/CA2320087C/en not_active Expired - Fee Related
- 1998-02-09 AU AU63200/98A patent/AU735084B2/en not_active Ceased
- 1998-02-09 IL IL13759898A patent/IL137598A/xx not_active IP Right Cessation
- 1998-02-09 EP EP98907382A patent/EP1052977A4/en not_active Withdrawn
- 1998-02-09 JP JP2000530199A patent/JP2002502812A/ja active Pending
- 1998-02-09 WO PCT/US1998/002265 patent/WO1999039699A1/en not_active Ceased
- 1998-02-09 KR KR1020007008518A patent/KR20010040646A/ko not_active Withdrawn
- 1998-02-09 CN CNB988135329A patent/CN1149078C/zh not_active Expired - Fee Related
-
2000
- 2000-08-07 SE SE0002831A patent/SE0002831L/ not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SE0002831D0 (sv) | 2000-08-07 |
| EP1052977A1 (en) | 2000-11-22 |
| AU735084B2 (en) | 2001-06-28 |
| AU6320098A (en) | 1999-08-23 |
| CN1149078C (zh) | 2004-05-12 |
| SE0002831L (sv) | 2000-09-28 |
| WO1999039699A1 (en) | 1999-08-12 |
| CN1284869A (zh) | 2001-02-21 |
| CA2320087A1 (en) | 1999-08-12 |
| CA2320087C (en) | 2006-12-19 |
| EP1052977A4 (en) | 2006-07-12 |
| IL137598A0 (en) | 2001-07-24 |
| IL137598A (en) | 2005-09-25 |
| JP2002502812A (ja) | 2002-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5863910A (en) | Treatment of chronic inflammatory disorders of the gastrointestinal tract | |
| EP2376077B1 (en) | Composition and method for treatment of diabetes | |
| JP2002502870A (ja) | 炎症性状態処置のための方法および組成物 | |
| KR20120082003A (ko) | 당뇨병 치료용 조성물 및 치료 방법 | |
| US20250161333A1 (en) | Compositions and methods for treating epilepsy | |
| US20090246301A1 (en) | Method for treating irritable bowel syndrome and other functional gastrointestinal disorders | |
| KR20010040646A (ko) | 위장관의 만성 염증성 질환의 치료방법 | |
| JP3614427B2 (ja) | 消化管吸収を増大する方法 | |
| JP2022508702A (ja) | 消化器系及び免疫系の障害を治療する為のヒト用栄養補助食品及び方法 | |
| JP2006517942A (ja) | 動物の免疫を向上するためのシステアミンを含む組成物 | |
| RU2485956C2 (ru) | Новая композиция для лечения побочных эффектов противораковой терапии | |
| JP7372269B2 (ja) | α－ラクトアルブミンに基づく医薬品または食品サプリメントの調製物 | |
| KR20010051558A (ko) | 아포 ｂ분비/ｍｔｐ억제제의 용도 | |
| JP2021519330A (ja) | ムメフラールを含む認知障害関連疾患の予防又は治療用組成物 | |
| JP2021518431A (ja) | 重度の便秘を治療するための組成物及び方法 | |
| CN114786711B (zh) | 预防或治疗肠易激综合征的药物组合 | |
| Grand et al. | Therapeutic strategies for pediatric Crohn disease | |
| US3940481A (en) | Treatment of hepatic coma with isomaltitol | |
| JP4370054B2 (ja) | 腸粘膜傷害の予防及び治療剤 | |
| US20250032516A1 (en) | Compositions and methods for treating epilepsy | |
| JP3831157B2 (ja) | 便臭改善剤 | |
| EP3463376A1 (en) | New treatment of sma | |
| US3591690A (en) | Method of treatment of diarrhea in piglet of 2-4 weeks of age | |
| KR0155976B1 (ko) | 항스트레스 의약조성물 | |
| TWI620566B (zh) | 三萜混合物用以治療多發性硬化的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20000804 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20000918 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |